MedTrace Logo

The Effect of Neurontin on Pain Management in the Acutely Burned Patient

NCT01265056 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2018-01-23

Study results available
· View outcomes & findings →

Summary

Burn patients have extreme pain. Opioids are the main agents used for analgesia. We therefore propose a single center study to fruther assess the efficacy of neuropathic agents in controlling the pain associated with acute thermal injury.

Conditions

Interventions

DRUG

Gabapentin

On Study day 1: 1200mg (single dose). Study day 2,3: 300mg TID, 900mg daily. Study day 4-7: 600mg TID 1800mg\* daily. Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\] Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\] \* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation.

DRUG

Placebo

Sugar Pill is administered similar to the protocol used for the investigational drug.

Sponsors & Collaborators

  • Lucy A Wibbenmeyer

    lead OTHER

Principal Investigators

  • Lucy Wibbenmeyer, MD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01265056 on ClinicalTrials.gov